Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors
Protocol ID
SJ ELiOT
Disease (Sub Disease)
Brain and Spinal Tumours (Medulloblastoma/ PNET)
Diagnosis Stage
Relapse/ refractory
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Collaborators
Eli Lilly and Company
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1
Age Eligibility
1 year to 25 years
International registry ID's
NCT04023669
| Study Title | Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors |
|---|---|
| Protocol ID | SJ ELiOT |
| Disease (Sub Disease) | Brain and Spinal Tumours (Medulloblastoma/ PNET) |
| Diagnosis Stage | Relapse/ refractory |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ St. Jude Children's Research Hospital |
| Collaborators | Eli Lilly and Company |
| Links | https://clinicaltrials.gov/ct2/show/NCT04023669 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 02/10/2019 |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 1 year to 25 years |
| International registry ID's | NCT04023669 |